Baidu
map

Sci Transl Med:研究发现笑气可改善抑郁

2021-06-11 Viho MedSci原创

使用25%的氧化亚氮气体进行单次吸入治疗,在快速缓解耐药性抑郁症的症状方面几乎与50%的氧化亚氮一样有效,而且不良副作用更少,且其效果持续时间更长,一些参与者的症状改善时间长达2周以上。

抑郁症是最常见的抑郁障碍,以显著而持久的心境低落为主要临床特征,是心境障碍的主要类型。 临床可见心境低落与其处境不相称,情绪的消沉可以从闷闷不乐到悲痛欲绝,自卑抑郁,甚至悲观厌世,可有自杀企图或行为;甚至发生木僵;部分病例有明显的焦虑和运动性激越;严重者可出现幻觉、妄想等精神病性症状。

每年有数以百万计的抑郁症患者没有好的治疗选择,尤其是那些处于自杀问题的患者,迫切需要有效的、快速的治疗方法,能够真正帮助他们。

6月9日,美国芝加哥大学医学院和华盛顿大学发表在Science Translational Medicine上的一项新研究发现,使用25%的氧化亚氮气体进行单次吸入治疗,在快速缓解耐药性抑郁症的症状方面几乎与50%的氧化亚氮一样有效,而且不良副作用更少,且其效果持续时间更长,一些参与者的症状改善时间长达2周以上。

氧化亚氮通常被称为 "笑气",经常被用作麻醉剂,在牙科和外科手术中提供短期疼痛缓解。在之前的一项研究中,调查人员对20名患者进行了一小时吸入50%氧化亚氮气体的效果测试,发现与安慰剂相比,它使患者的抑郁症状得到快速改善,并持续了至少24小时。然而,一些病人出现了副作用,包括恶心、呕吐和头痛。

因此,研究人员进行本次研究以探索过去50%的浓度是否过高,尝试通过降低剂量,找到临床用药黄金分割点,使临床效益最大化,并将负面的副作用降到最低。

在此次研究中,研究人员对20名患者重复了类似的方案,又增加了一个吸入25%氧化亚氮的环节。研究发现,25%氧化亚氮浓度,治疗效果也几乎与50%的氧化亚氮一样,而副作用只有四分之一。

此外,研究人员在较长的时间内观察了患者治疗后的临床抑郁症评分发现,仅在一次给药后,一些病人的抑郁症状的改善就持续了整个评估期。

给药后抑郁症状改善持续时间

这些结果表明,对于那些对其他治疗方法没有反应的严重抑郁症患者,氧化亚氮有望成为一种快速而有效的治疗方法。同时研究结果加强了非传统疗法可能是对典型抗抑郁药物没有反应的病人的可行选择的证据,为处于危机中的病人提供一个快速有效的治疗选择。

华盛顿大学医学院精神病学教授、耐药性抑郁症和神经刺激诊所主任Nagele博士说:"以往大约15%的抑郁症患者对标准的抗抑郁症治疗没有反应。"这些'治疗耐受性抑郁症'患者往往要忍受数年,甚至数十年的折磨,患的是削弱生命的抑郁症。我们并不真正知道为什么标准治疗方法对他们不起作用,尽管我们怀疑他们可能有与非耐药性抑郁症患者不同的大脑网络破坏。确定新的治疗方法,如一氧化二氮,以替代性途径为目标,对治疗这些人至关重要。"

同时Nagele也指出,尽管它有 "笑气 "的名声,但接受如此低剂量的病人实际上不会变得很高兴或很兴奋,只是被镇静后睡着。

虽然让非传统的抑郁症治疗方法被主流接受仍然具有挑战性,但研究人员希望这些结果以及其他类似的研究能够让那些不情愿的医生对这些药物的独特属性打开心扉。

"这些只是试点研究,"Nagele说。"但是我们需要被更大的医学界所接受,这样才能成为现实世界中病人真正可以使用的一种治疗方法。大多数精神病学家不熟悉一氧化二氮或如何使用它,所以我们必须向社会展示如何安全有效地提供这种治疗。我认为,人们会对将其纳入临床实践产生很大兴趣。"

随着更广泛的公众接受,Nagele希望这些结果能够为那些正在努力寻找适当的抑郁症治疗方法的患者打开大门。

原始出处:
P. Nagele el al., "A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression," Science Translational Medicine (2021). stm.sciencemag.org/lookup/doi/ … scitranslmed.abe1376

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1657508, encodeId=3019165e5088d, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Thu Aug 19 22:16:55 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067575, encodeId=5184206e575a7, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Jul 20 04:16:55 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753593, encodeId=ea771e53593cd, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sat Apr 16 15:16:55 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975268, encodeId=a5359e526853, content=不错的话题,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cdb2944259, createdName=63766754, createdTime=Sun Jun 20 23:30:14 CST 2021, time=2021-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611092, encodeId=dd88161109292, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jun 13 00:16:55 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972880, encodeId=20459e288063, content=对临床有一定帮助, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a1e1467554, createdName=zangyou1230, createdTime=Fri Jun 11 15:59:08 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972784, encodeId=22fd9e2784bc, content=有道理, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55965518958, createdName=ms7000000937988634, createdTime=Fri Jun 11 10:34:42 CST 2021, time=2021-06-11, status=1, ipAttribution=)]
    2021-08-19 bsmagic9140
  2. [GetPortalCommentsPageByObjectIdResponse(id=1657508, encodeId=3019165e5088d, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Thu Aug 19 22:16:55 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067575, encodeId=5184206e575a7, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Jul 20 04:16:55 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753593, encodeId=ea771e53593cd, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sat Apr 16 15:16:55 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975268, encodeId=a5359e526853, content=不错的话题,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cdb2944259, createdName=63766754, createdTime=Sun Jun 20 23:30:14 CST 2021, time=2021-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611092, encodeId=dd88161109292, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jun 13 00:16:55 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972880, encodeId=20459e288063, content=对临床有一定帮助, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a1e1467554, createdName=zangyou1230, createdTime=Fri Jun 11 15:59:08 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972784, encodeId=22fd9e2784bc, content=有道理, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55965518958, createdName=ms7000000937988634, createdTime=Fri Jun 11 10:34:42 CST 2021, time=2021-06-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1657508, encodeId=3019165e5088d, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Thu Aug 19 22:16:55 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067575, encodeId=5184206e575a7, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Jul 20 04:16:55 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753593, encodeId=ea771e53593cd, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sat Apr 16 15:16:55 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975268, encodeId=a5359e526853, content=不错的话题,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cdb2944259, createdName=63766754, createdTime=Sun Jun 20 23:30:14 CST 2021, time=2021-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611092, encodeId=dd88161109292, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jun 13 00:16:55 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972880, encodeId=20459e288063, content=对临床有一定帮助, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a1e1467554, createdName=zangyou1230, createdTime=Fri Jun 11 15:59:08 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972784, encodeId=22fd9e2784bc, content=有道理, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55965518958, createdName=ms7000000937988634, createdTime=Fri Jun 11 10:34:42 CST 2021, time=2021-06-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1657508, encodeId=3019165e5088d, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Thu Aug 19 22:16:55 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067575, encodeId=5184206e575a7, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Jul 20 04:16:55 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753593, encodeId=ea771e53593cd, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sat Apr 16 15:16:55 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975268, encodeId=a5359e526853, content=不错的话题,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cdb2944259, createdName=63766754, createdTime=Sun Jun 20 23:30:14 CST 2021, time=2021-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611092, encodeId=dd88161109292, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jun 13 00:16:55 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972880, encodeId=20459e288063, content=对临床有一定帮助, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a1e1467554, createdName=zangyou1230, createdTime=Fri Jun 11 15:59:08 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972784, encodeId=22fd9e2784bc, content=有道理, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55965518958, createdName=ms7000000937988634, createdTime=Fri Jun 11 10:34:42 CST 2021, time=2021-06-11, status=1, ipAttribution=)]
    2021-06-20 63766754

    不错的话题,学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1657508, encodeId=3019165e5088d, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Thu Aug 19 22:16:55 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067575, encodeId=5184206e575a7, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Jul 20 04:16:55 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753593, encodeId=ea771e53593cd, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sat Apr 16 15:16:55 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975268, encodeId=a5359e526853, content=不错的话题,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cdb2944259, createdName=63766754, createdTime=Sun Jun 20 23:30:14 CST 2021, time=2021-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611092, encodeId=dd88161109292, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jun 13 00:16:55 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972880, encodeId=20459e288063, content=对临床有一定帮助, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a1e1467554, createdName=zangyou1230, createdTime=Fri Jun 11 15:59:08 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972784, encodeId=22fd9e2784bc, content=有道理, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55965518958, createdName=ms7000000937988634, createdTime=Fri Jun 11 10:34:42 CST 2021, time=2021-06-11, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1657508, encodeId=3019165e5088d, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Thu Aug 19 22:16:55 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067575, encodeId=5184206e575a7, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Jul 20 04:16:55 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753593, encodeId=ea771e53593cd, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sat Apr 16 15:16:55 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975268, encodeId=a5359e526853, content=不错的话题,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cdb2944259, createdName=63766754, createdTime=Sun Jun 20 23:30:14 CST 2021, time=2021-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611092, encodeId=dd88161109292, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jun 13 00:16:55 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972880, encodeId=20459e288063, content=对临床有一定帮助, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a1e1467554, createdName=zangyou1230, createdTime=Fri Jun 11 15:59:08 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972784, encodeId=22fd9e2784bc, content=有道理, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55965518958, createdName=ms7000000937988634, createdTime=Fri Jun 11 10:34:42 CST 2021, time=2021-06-11, status=1, ipAttribution=)]
    2021-06-11 zangyou1230

    对临床有一定帮助

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1657508, encodeId=3019165e5088d, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Thu Aug 19 22:16:55 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067575, encodeId=5184206e575a7, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Tue Jul 20 04:16:55 CST 2021, time=2021-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753593, encodeId=ea771e53593cd, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Sat Apr 16 15:16:55 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975268, encodeId=a5359e526853, content=不错的话题,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cdb2944259, createdName=63766754, createdTime=Sun Jun 20 23:30:14 CST 2021, time=2021-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611092, encodeId=dd88161109292, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jun 13 00:16:55 CST 2021, time=2021-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972880, encodeId=20459e288063, content=对临床有一定帮助, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a1e1467554, createdName=zangyou1230, createdTime=Fri Jun 11 15:59:08 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972784, encodeId=22fd9e2784bc, content=有道理, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55965518958, createdName=ms7000000937988634, createdTime=Fri Jun 11 10:34:42 CST 2021, time=2021-06-11, status=1, ipAttribution=)]
    2021-06-11 ms7000000937988634

    有道理

    0

相关资讯

Nat Neurosci:GWAS和荟萃分析揭示抑郁症的遗传结构和新治疗方向

抑郁症是一种最常见的神经精神疾病,在美国,该疾病的一生患病率超过20%。

Psychological Medicine:抑郁症与心血管疾病有关

抑郁症与代谢改变有关,这可能是抑郁症与心血管疾病之间的联系机制

Acta Psychiatrica Scandinavica:代谢组学谱可用于区分焦虑症和抑郁症

炎症和动脉粥样硬化代谢组谱可能与抑郁的存在唯一相关,而与焦虑无关。代谢组特征可能是这些高度相关但又不相同的情绪状态的一个显著特征。

你几点睡觉?84万人基因研究发现,睡眠中点提前一小时可将抑郁风险降低23%

一项针对84万人的遗传学研究发现,将睡眠时间提前一个小时,就能将抑郁症的风险降低23%。

成都一名学生坠亡事件引发的思考|微笑抑郁,你是吗?

近日,成都49中学生坠亡事件一直在舆论发酵,他的离去,不仅让父母亲人无法理解、悲痛不已,也在网络上掀起了一场舆论风暴。

CJASN:抑郁症将提高肾功能下降风险

慢性肾脏病(CKD)是全球范围内心血管疾病、肾衰竭和死亡的主要风险因素。2012年,中国成年人中CKD的总体患病率为11%。也就是说,中国的CKD患者人数估计约为1.195亿。

拓展阅读

Translational Psychiatry:亚临床抑郁的应激反应特征及其对大脑网络的影响

StD个体中应激相关网络的功能异常可能是影响抑郁症状的重要机制。DMN SC-FC耦合与皮质醇水平的结合在区分StD个体和健康对照中具有较高的预测能力。

躯体疾病共病抑郁的治疗与药物选择

躯体障碍是一种以对一个或多个躯体症状的过度关注和焦虑为特征的心理疾病。患者往往对自己的身体健康状况过度担忧,即使经过反复的医学检查,也无法找到明确的器质性病变。

Translational Psychiatry :脑内“失望中心”的兴奋:系统性综述抑郁症中缰核功能障碍

缰核的过度兴奋是抑郁症的重要驱动因素,而临床研究支持缰核的连接、体积和分子变化均与抑郁症相关。未来研究需要进一步关注性别差异及分子层面的深度解析。

The British Journal of Psychiatry:早期抗生素暴露与神经发育障碍:系统评价和Meta分析揭示复杂关联

早期抗生素暴露与自闭症谱系障碍、注意缺陷多动障碍以及重度抑郁症风险的增加存在一定关联,但在考虑遗传和家庭背景等混杂因素后,这些关联在某些分析中被削弱,尤其是使用兄弟姐妹对照的研究未能确认这些关联。

CGP论著 | 午睡30~75min,夜间睡眠6~9h可能降低老年人抑郁症状发生风险

建议老年人每天午睡30~75 min,适度的午睡时长有效降低老年人发生抑郁症状的风险,同时夜间睡眠6~9 h降低抑郁症状的发生风险,对老年人群抑郁症的早期防控具有一定的意义。

JACC:Advances:当患者抑郁时,TAVR 存活率降低

JACC:Advances 上一项分析显示,有症状主动脉瓣狭窄老年患者中,术前抑郁者经导管主动脉瓣置换术(TAVR)后长期生存率低,研究介绍相关情况、结论及局限性,给出参考文献。

Baidu
map
Baidu
map
Baidu
map